Revelation Biosciences (REVB) is experiencing a price increase of 15.61% in pre-market trading, reaching a 20-day high.
The company will showcase new clinical data from its PRIME study at an upcoming conference, which focuses on its investigational therapy, Gemini. This therapy aims to rebalance immune response in patients with stage 3 and 4 chronic kidney disease, indicating significant implications for disease progression. The urgent market demand for effective treatments for acute kidney injury further highlights the potential commercial value of Gemini therapy.
This presentation could enhance investor confidence and attract attention to Revelation's innovative approaches in treating kidney diseases, potentially leading to increased market interest.
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
